Please login to the form below
dermatitis
This page shows the latest dermatitis news and features for those working in and with pharma, biotech and healthcare.
New data keeps AbbVie’s star pipeline therapies on track
It also unveiled mid-stage data on its JAK1 inhibitor upadacitinib in atopic dermatitis, adding another clinical win to earlier successes in rheumatoid arthritis. ... Upadacitinib is already in a phase III trial in atopic dermatitis and picked up a
Latest news
-
Gilead, Galapagos JAK inhibitor clears phase II test
Like filgotinib, upadacitinib is also being tested in a string of other indications, including psoriatic arthritis, Crohn’s disease, ulcerative colitis and atopic dermatitis.
-
AZ, Amgen’s first-in-class asthma drug gets breakthrough status
Regeneron’s new candidate Dupixent (dupilumab), an IL-4 and IL-13 inhibitor that is already approved for atopic dermatitis.
-
Realm toppled by second mid-stage trial flop
Shares in UK-listed Ream Therapeutics went into free fall yesterday after its lead drug for atopic dermatitis failed to show a benefit in a phase II trial, it’s second ... We are conducting a full review to determine whether there is a path forward for
-
Dupixent bounce-back helps stem diabetes declines at Sanofi
A sudden uptick in sales of atopic dermatitis drug Dupixent helped offset a steep decline in diabetes sales at Sanofi in the second quarter, and chief executive Olivier Brandicourt (pictured) is
-
Daily Brief: Biosimilars ready to pounce on Humira, Hong Kong could rival Nasdaq, Kymab's OX40 candidate
Kymab says the data supports taking KY1005 into patient phase II studies in patients with atopic dermatitis. ... The phase IIa trial in atopic dermatitis is expected to begin in late 2018.
More from news
Approximately 9 fully matching, plus 56 partially matching documents found.
Latest Intelligence
-
Leo has its eyes on the prize
Psoriasis and dermatitis may seem the same in everybody but maybe the picture is more like it is in cancer where you have subsets. ... Bridging the gap. Leo is tracking increases in atopic dermatitis across Europe while psoriasis levels show no signs of
-
Pharma deals continue to slide
Phase II MAb to block IL-13 for treatment of atopic dermatitis.
-
Deal Watch September 2016
as well as other autoimmune disorders plus VTP-38543 for atopic dermatitis.
-
Deal Watch July 2016
AstraZeneca is developing tralokinumab for severe asthma, where it is in phase III development, and has recently completed a phase IIb study in patients with atopic dermatitis.
-
Allergies and asthma
Early prevention is recommended. Allergic diseases (eg food allergies, rhinitis, asthma, atopic dermatitis) usually start in childhood but can develop at any age. ... of the hypo-allergenic milk formula on cow's milk allergy and atopic dermatitis (AD).
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest appointments
-
Dr Desiree Luthman joins Verona Pharma
atopic dermatitis in the US.
-
Ziarco appoints Mike Grey to board of directors
Concerning his appointment, Grey said: “ I am delighted to join Ziarco's board, as the company has a strong leadership team and promising lead compounds for the treatment of atopic dermatitis
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Research Partnership launches new patient Living with Atopic Dermatitis (US) 2017 report
Research Partnership launches new patient Living with Atopic Dermatitis (US) 2017 report. ... Living with Atopic Dermatitis (AD) is a study conducted amongst 100 adults and 50 caregivers in the US.
-
Research Partnership has published a new patient Living with Atopic Dermatitis (US) report
Research Partnership has published a new patient Living with Atopic Dermatitis (US) report. ... An attitudinal segmentation is included to help identify the unique groups of patients Atopic Dermatitis.
-
Bringing sufferers out of the shadows – Reducing the emotional impact of living with Atopic Dermatitis
Bringing sufferers out of the shadows – Reducing the emotional impact of living with Atopic Dermatitis. ... Atopic dermatitis (AD) or eczema is a chronic inflammatory skin disease, which, although not as debilitating as other chronic conditions, can
-
Research Partnership
We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical industry, we provide custom solutions and strategic recommendations that go beyond research,
-
Research Partnership
We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical industry, we provide custom solutions and strategic recommendations that go beyond research,
More from PMHub
Approximately 3 fully matching, plus 2 partially matching documents found.
Featured jobs
- Lead Medical Copywriter, Healthcare Brand Communications, London
-
Excellent package
- Account Manager, Healthcare Advertising
-
Salary TBC
- Senior Account Manager / Account Director - Med Comms
-
Great salary and benefits
-
Account Director - Digital
-
Great salary and benefits
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
-
SENIOR MEDICAL WRITER IN ONCOLOGY
-
Up to £60, 000.00 pension bonus
- Senior Medical Writer (Remote Working)
-
Competitive Salary Offered
-
Scientific Director
-
Highly Competitive Salary &Benefits
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
-
Account Director
-
Negotiable
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
- Director Healthcare PR Communications
-
Salary TBC
- Experienced Editor, London, Medical Communications
-
Competitive package
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 benefits
-
Scientific Team Lead
-
Competitive Salary
-
Senior Account Manager - Med Comms
-
Highly Competitive Salary &Benefits
- Senior Account Director development role to Business Director, H...
-
Excellent package
Subscribe to our email news alerts
- Tackling a formidable foe
- Cancer care – the power of new technologies
- AcelRX’s potent opioid tablets set to win FDA backing for pain relief
- New leader at Medivir after setbacks
- Roche preps new Kadcyla filings after phase 3 trial win
- Porterhouse Medical Group boosts its scientific services team with two new appointments
PMHub
Market Access Transformation
Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...
Latest intelligence
- Tackling a formidable foe
- Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
- Cancer care – the power of new technologies
- With patient numbers set to soar, how can we make a difference?...
- Redefining communications excellence
- How to be heard in today’s multichannel, multistakeholder, multimedia world...
Quick links
Infographics
